Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622
This examiner grants 38% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17776961 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Non-Final OA | The Broad Institute, Inc. |
| 18647336 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17666493 | SIMULTANEOUS DEHYDRATION OF GLUCOSE AND XYLOSE TO FURFURALS USING HETEROGENOUS SOLID ACID CATALYSTS | Non-Final OA | Alliance for Sustainable Energy, LLC |
| 18549693 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS FOR SLOWING OF PARKINSON'S DISEASE PROGRESSION | Non-Final OA | Eli Lilly and Company |
| 17962610 | PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES | Final Rejection | Medimmune Limited |
| 17421498 | COMPOUNDS AND TREATMENTS THAT ENHANCE ENTERIC NERVOUS SYSTEM FUNCTION | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18101627 | COMBINATION CANCER THERAPIES | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 17276032 | COMBINATION CANCER THERAPIES | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 17799795 | SMALL MOLECULE REGULATORS OF NOTCH1 AND USES THEREOF | Final Rejection | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 17617479 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | Final Rejection | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 18550486 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18516589 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | Non-Final OA | C4 Therapeutics, Inc. |
| 17293929 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | Non-Final OA | NIPPON SHINYAKU CO., LTD. |
| 18550724 | A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | Non-Final OA | Sage Therapeutics, Inc. |
| 18556649 | CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT | Non-Final OA | HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH |
| 18005847 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Non-Final OA | GW Research Limited |
| 18358518 | INJECTABLE FORMULATION WITH ENHANCED STABILITY CONTAINING DEXIBUPROFEN AND ARGININ AND THEIR MEDICINE VESSEL FOR INJECTION | Non-Final OA | AMOS PHARM |
| 18173962 | THERAPEUTIC TARGETING OF GPR68 TO INDUCE FERROPTOSIS | Non-Final OA | University Of Maryland, Baltimore |
| 18120311 | MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF | Non-Final OA | HUYABIO International, LLC |
| 17912108 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Non-Final OA | STALICLA SA |
| 18206506 | BIOLOGICAL ACTIVITIES OF 5-(2-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)ETHYL)-5-AZASPIRO[2.4]-HEPTAN-7-OL CRYSTALLINE, PHOSPHORIC ACID SALT AND ITS ENANTIOMERS | Non-Final OA | Advenchen Pharmaceuticals, LLC |
| 17434587 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | Non-Final OA | CULLGEN (SHANGHAI), INC. |
| 18136797 | TREATMENT OF BRAIN COPPER DISORDERS | Non-Final OA | Sasha A. PHILBERT |
| 17596832 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Non-Final OA | Ascendis Pharma A/S |
| 17610753 | Ruthenium (II) Complexes and Their Use as AntiCancer Agents | Non-Final OA | University of Zürich |
| 17924717 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Non-Final OA | Suzhou AlphaMa Biotechnology Co., Ltd. |
| 17920233 | ORAL SOLID MELOXICAM FORMULATIONS FOR THE TREATMENT OF ACUTE PAIN | Final Rejection | Viatris Specialty LLC |
| 17907496 | METHODS OF REDUCING FUSARIUM CONTAMINATION | Final Rejection | Taminco BV |
| 17819111 | METHOD FOR TREATING BOTULINUM TOXIN POISONING | Final Rejection | Catalyst Pharmaceuticals, Inc. |
| 17607048 | REBAMIPIDE FOR USE IN PREVENTION AND/OR TREATMENT OF SYNUCLEINOPATHIES | Non-Final OA | SQUARE POWER LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy